Last reviewed · How we verify
LB1410
At a glance
| Generic name | LB1410 |
|---|---|
| Sponsor | L & L Bio Co., Ltd., Ningbo, China |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer (PHASE2, PHASE3)
- A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
- A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001） (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LB1410 CI brief — competitive landscape report
- LB1410 updates RSS · CI watch RSS
- L & L Bio Co., Ltd., Ningbo, China portfolio CI